Divine Skin enters Brazil
This article was originally published in The Rose Sheet
Executive Summary
Miami Beach-based biotech firm launches its first Latin American subsidiary - DS Laboratories do Brasil Ltd. - complete with local office, resident pharmacist and sales force in place. "This is a major milestone in the meteoric growth of Divine Skin worldwide," says Daniel Khesin, founder and chief executive, adding: "We expect Brazilian sales to be visible in 2010 figures and to contribute strongly in 2011 and beyond." Firm's flagship DS Laboratories brand expects its Nia radiant color shampoo and conditioner and Nirena pH-balanced feminine cleanser to roll out first in Brazil, as they are considered Level-1 cosmetics of minimal risk, Divine Skin indicates in its Oct. 4 release. The company's Oligo.DX cellulite-reducing gel is concluding 60-day efficiency testing, required of Level-2 cosmetics in Brazil, and has demonstrated an "astounding" 90% success rate, according to the firm. Efficiency tests for Divine Skin's Revita hair-growth-stimulating shampoo should wrap by the end of October, and tests for the rest of the DS Laboratories line should be finished by the year's end, Divine Skin notes. Firm cites Brazil's gross domestic product of $2 tril. and population growth rate of 1.2% annually. Divine Skin launched a dedicated consumer health division in July (1"The Rose Sheet" July 12, 2010)
You may also be interested in...
Divine Skin Launches Consumer Health Division
Biotechnology firm Divine Skin parlays its knowledge in hair and skin technology into a division dedicated to marketing OTC and pharmaceutical drugs
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.